Stock Analysis on Net
Stock Analysis on Net

GlaxoSmithKline PLC (NYSE:GSK)

This company has been moved to the archive! The financial data has not been updated since February 27, 2015.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

GlaxoSmithKline PLC, common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Short-term borrowings 7.24 6.63 8.75 6.57 0.69
Trade payables 6.86 6.51 6.43 6.25 5.07
Wages and salaries 2.35 2.49 2.21 2.37 2.20
Social security 0.22 0.26 0.27 0.27 0.27
Other payables 0.74 2.15 2.12 0.74 0.70
Deferred income 0.15 0.40 0.39 0.09 0.17
Customer return and rebate accruals 4.36 3.80 3.95 4.06 3.86
Contingent consideration 0.26 0.01 0.00 0.00 0.00
Other accruals 4.62 4.15 4.05 4.12 4.03
Trade and other payables 19.58% 19.76% 19.42% 17.91% 16.31%
Derivative financial instruments 0.99 0.30 0.15 0.43 0.45
Current tax payable 2.32 3.45 3.31 4.00 2.48
Short-term provisions 2.57 2.36 1.67 7.63 10.37
Current liabilities 32.71% 32.50% 33.31% 36.54% 30.30%
Long-term borrowings 38.97 36.72 35.37 29.71 35.07
Deferred tax liabilities 1.09 1.65 2.42 2.00 1.67
Pensions and other post-employment benefits 7.82 5.20 7.49 7.52 6.33
Other provisions 1.34 1.31 1.69 1.21 2.14
Derivative financial instruments 0.02 0.01 0.00 0.00 0.01
Accruals and deferred income 0.23 0.24 0.18 0.31 0.24
Contingent consideration 3.98 2.28 0.00 0.00 0.00
Other payables 1.70 1.53 3.28 1.21 1.16
Other non-current liabilities 5.91% 4.05% 3.45% 1.52% 1.41%
Non-current liabilities 55.15% 48.94% 50.42% 41.97% 46.63%
Total liabilities 87.86% 81.44% 83.73% 78.51% 76.92%
Share capital 3.29 3.17 3.25 3.38 3.36
Share premium account 6.79 6.17 4.88 4.07 3.38
Retained earnings -5.10 2.17 1.57 8.20 11.32
Other reserves 5.51 5.12 4.31 3.90 2.99
Shareholders’ equity 10.49% 16.63% 14.01% 19.55% 21.04%
Non-controlling interests 1.66 1.94 2.26 1.94 2.03
Total equity 12.14% 18.56% 16.27% 21.49% 23.08%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. GlaxoSmithKline PLC current liabilities as a percentage of total liabilities and equity decreased from 2012 to 2013 but then slightly increased from 2013 to 2014.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. GlaxoSmithKline PLC non-current liabilities as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 exceeding 2012 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. GlaxoSmithKline PLC total liabilities as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 exceeding 2012 level.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. GlaxoSmithKline PLC shareholders’ equity as a percentage of total liabilities and equity increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.